4/30/2023 0 Comments Sweden pauses modernaNorway already recommends the Cominarty vaccine to minors and said on Wednesday that it was reiterating this. The vaccine is not approved for people under age 18 in the United States. vaccine safety monitoring databases has also suggested that Moderna's vaccine may carry a higher risk of myocarditis among young people. The benefits of shots based on so-called mRNA technology used by both Moderna and Pfizer-BioNTech in preventing COVID-19 continue to outweigh the risks, regulators in the United States, EU and the World Health Organization have said.ĭata suggests reported cases of rare heart inflammation are relatively higher after Moderna's vaccine compared with the Pfizer/BioNTech shots, Canadian health officials said last week.Īlthough both vaccines are based on mRNA technology, the Pfizer shot contains 30 micrograms of vaccine per dose compared with 100 micrograms in the Moderna vaccine.ĭata from one of two U.S. The EMA's safety committee concluded in July that inflammatory heart conditions can occur in very rare cases following vaccination with Comirnaty or Spikevax, more often in younger men after the second dose. The Danish Health Authority said it had made the decision even as "heart inflammation is an extremely rare side effect that often has a mild course and goes away on its own". Sweden and Denmark said they now recommended the Comirnaty vaccine, from Pfizer/BioNTech, instead. Final data was expected within a month, it added. It referred to data from a yet unpublished Nordic study, which would now be sent to the European Medicines Agency (EMA) for further assessment. there is a suspicion of an increased risk of heart inflammation, when vaccinated with Moderna," the Danish Health Authority said in a statement. study that has yet to undergo peer review young males under 20 are up to six times more likely to develop myocarditis after contracting COVID-19 than those who have been vaccinated.ĭenmark said that, while it used the Pfizer/BioNTech vaccine as its main option for people aged 12-17 years, it had decided to pause giving the Moderna vaccine to people below 18 according to a "precautionary principle". The risk of myocarditis is substantially increased for those who contract COVID-19, and vaccination is the best way to protect against this."Īccording to one U.S. "These are typically mild cases and individuals tend to recover within a short time following standard treatment and rest. Shares of Moderna fell 4.9%, or $16.08, to $316.11 in afternoon trading.Ī Moderna spokesperson said in an email the company was aware of the decisions by regulators in Denmark and Sweden to pause the use of its vaccine in younger individuals because of the rare risk of myocarditis and or pericarditis. Sweden, which opted against wide-ranging lockdowns and relied mostly on voluntary recommendations throughout the pandemic, has relatively low levels of cases, hospitalisations and deaths currently compared with other European countries."The connection is especially clear when it comes to Moderna's vaccine Spikevax, especially after the second dose," the health agency said, adding the risk of being affected was very small. Of 139,651 tests last week, 3% came back positive. ![]() People who are patients or working in healthcare should still get tested, as should those who have been in contact with someone confirmed to be positive. The new testing guidelines come into effect on Nov. The vaccine protects well, above all against severe disease but also against infection and the spread of infection," health agency official Britta Bjorkholm told a news conference.Īround 85% of all Swedes aged 16 and up have had one dose of vaccine and 80% have had two shots or more. ![]() "We must test those who are most at risk of being infected with COVID-19. The health agency also said it was time to cease wide-scale testing and will remove the recommendation for testing for those who are fully vaccinated, even if they are displaying symptoms. The European Medicines Agency approved the use of Comirnaty in May, while Spikevax was given the nod for children aged over 12 in July.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |